Background and Aims: LANDMARC (LongitudinAl NationwiDe StuDy On Management And Real World OutComes of Diabetes In India, CTRI/2017/05/008452) is the first prospective, observational, longitudinal study to understand the development of diabetes complications over a 3-year (yr) period in India with high number of sites (450) and a larger cohort of patients.

Methods: Adult subjects with T2D treated with ≥2 antihyperglycemic drugs (controlled/uncontrolled on A1c) were enrolled for assessment and baseline characteristics were analyzed using descriptive statistics.

Results: Of 6332 enrolled subjects, 6280 were eligible for baseline assessment. Mean (SD) age, BMI, and T2D duration were 52.12 (9.15) yr, 27.21 (4.59) kg/m2, and 8.57 (5.62) yr, respectively. Baseline A1c (n=4613; mean [SD]) was 8.0 (1.6) % and 1331 subjects (29%) hadA1c <7.0%. Mean (SD) FPG (n=5176) and PPG (n=5067) were 142.6 (50.4) mg/dL and 205.2 (71.8) mg/dL, respectively. Approximately 70% of subjects (n=4556) received only oral antihyperglycemic drugs OADs and 1687 subjects received both OADs and injectables (INJ). Biguanides (n=5829, 92.8%) and sulfonylureas (n=4785, 76.2%) were the most frequently prescribed OADs, and majority of subjects (n=2766, 44.3%) were prescribed two OAD classes. The mean (SD) duration (yr) of T2D was shorter in subjects receiving OADs (7.58 [4.88]) than INJ (11.01 [6.69]) or OAD+INJ (11.21 [6.57]). Most of the eligible subjects (n/N=3266/6280) had ≥1 CV risk factors; hypertension (n=2566, 40.9%) and dyslipidemia (n=1619, 25.8%) being most prevalent. Subjects with baseline A1c >7% to ≤8% had higher incidence of hypertension and dyslipidemia than other A1c groups. Neuropathy was the most common complication (n/N=728/6280, 11.6%) followed by nephropathy (n/N=153/6280, 2.44%).

Conclusion: These real-world data provide first insights on the epidemiology and treatment landscape of people with T2D in India.

Disclosure

R. Ghosh: Employee; Self; Sanofi. A.K. Das: None. A. Unnikrishnan: Other Relationship; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddys Laboratories, Eli Lilly and Company, Eris Pharmaceuticals, Ipca Laboratories Ltd., MSD, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Sanofi. S. Kalra: None. H. Thacker: None.

Funding

Sanofi

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.